[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …
tomography (PET) is emerging to become a reference imaging tool for the staging and …
Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for …
KM Chow, WZ So, HJ Lee, A Lee, DWT Yap… - European urology, 2023 - Elsevier
Context Whether prostate-specific membrane antigen positron emission tomography (PSMA-
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
Radiotheranostics in oncology: making precision medicine possible
EO Aboagye, TD Barwick… - CA: a cancer journal for …, 2023 - Wiley Online Library
A quintessential setting for precision medicine, theranostics refers to a rapidly evolving field
of medicine in which disease is diagnosed followed by treatment of disease‐positive …
of medicine in which disease is diagnosed followed by treatment of disease‐positive …
[HTML][HTML] Diagnostic performance and safety of positron emission tomography with 18F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate-to very …
DS Surasi, M Eiber, T Maurer, MA Preston, BT Helfand… - European urology, 2023 - Elsevier
Abstract Background Radiohybrid (rh) 18 F-rhPSMA-7.3 is a novel high-affinity prostate-
specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) …
specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) …
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2023 - Springer
Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
Advances in Prostate‐Specific Membrane Antigen (PSMA)‐Targeted Phototheranostics of Prostate Cancer
H Wang, Z He, XA Liu, Y Huang, J Hou… - Small …, 2022 - Wiley Online Library
With the advent of the era of precision medicine, prostate‐specific membrane antigen
(PSMA)‐targeted theranostic strategies have had a profound impact on prostate cancer …
(PSMA)‐targeted theranostic strategies have had a profound impact on prostate cancer …
The PRIMARY score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis
Multiparametric MRI (mpMRI) is validated for the diagnosis of clinically significant prostate
cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has …
cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has …
PSMA PET in imaging prostate cancer
I Tsechelidis, A Vrachimis - Frontiers in oncology, 2022 - frontiersin.org
After prostate malignancy diagnosis, precise determination of disease extent are
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …
[HTML][HTML] Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but various areas of management still lack high …
prostate cancer have improved outcomes, but various areas of management still lack high …